• Xiao-Tao Chen, Philip Pitis, Guodong Liu, Catherine Yuan, Dimitar Gotchev, Conrad L Cowan, David H Rominger, Michael Koblish, Scott M Dewire, Aimee L Crombie, Jonathan D Violin, and Dennis S Yamashita.
• Trevena, Inc., 1018 West 8th Avenue, Suite A, King of Prussia, Pennsylvania 19406, United States.
• J. Med. Chem. 2013 Oct 24;56(20):8019-31.

AbstractThe concept of "ligand bias" at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another. There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs. The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events. Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 ((R)-30). This novel molecule demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clinical development. It is currently being evaluated in human clinical trials for the treatment of acute severe pain.

35 keywords...

hide…